Tech Company Financing Transactions
ReViral Funding Round
CR-CP Life Science Fund, Andera Partners and Brace Pharma invested in a $44 million Series C capital raise for ReViral. The round was announced by the company on 8/26/2020.
Transaction Overview
Company Name
Announced On
8/26/2020
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, our wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2530 Meridian Pkwy. 2nd Floor
Durham, NC 27713
USA
Durham, NC 27713
USA
Phone
Undisclosed
Website
Email Address
Overview
ReViral is built on the confidence that, with a dedicated team and world-class science, we can develop transformative antiviral therapies to help the world's most at-risk populations. Our first focus for this mission is Respiratory Syncytial Virus (RSV).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alex Sapir
Chief Financial Officer
Alan Musso
Chief Medical Officer
Seth Hetherington
Chief Operating Officer
Eddy Littler
Chief Scientific Officer
Stuart Cockerill
Founder
Neil Mathews
Browse more venture capital transactions:
Prev: 8/26/2020: Split venture capital transaction
Next: 8/26/2020: Connect Biopharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs